We also found that L-NAME treatment markedly abolished the effects of GPR87 overexpression, indicating that the inhibition of eNOS can inhibit GPR87-induced metastatic properties in lung adenocarcinoma. This evidence concerns the gene NOS3 and lung adenocarcinoma.